Evidence map›Paper›PMID 31815521›Full record

ArticleAmerican journal of respiratory and critical care medicine2020

Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test.

Hana Müllerová, Mark T Dransfield, Byron Thomashow, Paul W Jones, Stephen Rennard, Niklas Karlsson, Malin Fageras, Norbert Metzdorf, Stefano Petruzzelli, Jean Rommes and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04320342 (A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04320342 phase3completednot on this mapstarted 2022, after this paper: background citation

A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

TypeinterventionalSponsorChiesi Farmaceutici S.p.A.Ran2022 to 2026Enrolled3,433ConditionsCOPD, COPD ExacerbationArmsBeclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.International journal of chronic obstructive pulmonary disease · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hana MüllerováValue Evidence and Outcomes, Global Medical R&D, GlaxoSmithKline, Uxbridge, United Kingdom.
Mark T DransfieldLung Health Center, University of Alabama at Birmingham, Birmingham, Alabama.
Byron ThomashowCOPD Foundation, Miami, Florida.
Paul W JonesValue Evidence and Outcomes, Global Medical R&D, GlaxoSmithKline, Uxbridge, United Kingdom.
Stephen RennardUniversity of Nebraska, Omaha, Nebraska.
Niklas KarlssonBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Malin FagerasBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Norbert MetzdorfBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Stefano PetruzzelliChiesi Farmaceutici S.p.A., Parma, Italy.
Jean RommesCOPD Foundation, Miami, Florida.
Frank C SciurbaDivision of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; and.
Maggie TabbererValue Evidence and Outcomes, Global Medical R&D, GlaxoSmithKline, Uxbridge, United Kingdom.
Debora MerrillCOPD Foundation, Miami, Florida.
Ruth Tal-SingerValue Evidence and Outcomes, Medical Innovation, Global Medical R&D, GlaxoSmithKline, Collegeville, Pennsylvania.

Funding

UAB Mentoring Program in COPD Patient Oriented ResearchK24HL140108 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DRANSFIELD, MARK T · 2018 to 2022
$439k
NHLBI NIH HHS K24 HL140108
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overChronic DiseaseCritical CareFemaleHumansMaleMiddle AgedNursing AssessmentPulmonary Disease, Chronic ObstructiveRespiratory Care UnitsSurveys and QuestionnairesUnited States

Identifiers

PMID31815521
PMCPMC7193857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.